Strategy
US Growth Equities
The Driehaus US Growth Equities team focuses on investing in US-listed equities of public companies with market capitalizations between $100 million and $15 billion, through the Driehaus Micro Cap Growth, Driehaus Small Cap Growth, Driehaus Small/Mid Cap Growth and Driehaus Life Sciences strategies. The strategies provide investors with high active share portfolios of companies experiencing positive fundamental change in addition to exposure to positive growth inflections, earnings surprises and earnings revisions, factors that are positively correlated to alpha generation. The team is led by Jeff James who began his portfolio management career at Driehaus in 1998. He is supported by six analysts that combined have over 50 years of Driehaus research experience.
Institutional Investors
Our institutional sales team will be pleased to address questions and requests related to separately managed accounts and/or institutional commingled vehicles that employ our investment strategies.
Ask Us!
Driehaus Micro Cap Growth Strategy
View DetailsDriehaus Micro Cap Growth Strategy
The strategy seeks to outperform the Russell Microcap® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Jan 01, 1996
- Total Strategy Assets
As of Nov 30, 2022
- $1765M
Separately Managed Accounts
- Open to New Investors
- No
Funds
Driehaus Small Cap Growth Strategy
View DetailsDriehaus Small Cap Growth Strategy
The strategy seeks to outperform the Russell 2000® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Jan 01, 1980
- Total Strategy Assets
As of Nov 30, 2022
- $2538M
Separately Managed Accounts
- Open to New Investors
- Yes
Funds
Driehaus Small/Mid Cap Growth Strategy
View DetailsDriehaus Small/Mid Cap Growth Strategy
The strategy seeks to outperform the Russell 2500® Growth Index over full market cycles.
Facts
- Strategy Inception Date
- Feb 01, 2012
- Total Strategy Assets
As of Nov 30, 2022
- $1228M
Separately Managed Accounts
- Open to New Investors
- Yes
Funds
Driehaus Life Sciences Strategy
View DetailsDriehaus Life Sciences Strategy
The strategy intends to exploit the inefficiencies in how markets assign risk to development-stage and early-commercial stage healthcare companies.
Facts
- Strategy Inception Date
- Feb 01, 2019
- Total Strategy Assets
As of Nov 30, 2022
- $203M
Separately Managed Accounts
- Open to New Investors
- Yes
Philosophy & Process
The team employs a growth-oriented investment philosophy focusing on identifying company-specific growth inflection points and exploiting associated marketplace inefficiencies. Core to the philosophy are the beliefs that: earnings are the primary driver of equity prices over time, market expectations tend to be ‘anchored’ to historical information and points of inflection therefore introduce dislocations between market expectations and fundamentals which generate significant alpha capture opportunities. The team combines fundamental, macro/sector/industry and behavioral analysis in its investment process together with a nimble/active investment approach to quickly identify inefficiencies and generate a portfolio, which uniquely seeks to achieve superior aggregate growth rates as well as superior risk characteristics.
Featured Commentary
Checking in with Loan Officers
Since 1964, The Board of Governors of the Federal Reserve System has conducted the Senior Loan Officer Opinion Survey on Bank Lending Practices (SLOOS) which is designed to provide information on bank credit availability and loan demand. Administered quarterly since 1992, it can be a useful tool for investors to gauge developments in the credit cycle which is important both for macroeconomic assessments and bank stock investing.
Driehaus Small Mid Cap Growth Strategy September 2022 Commentary with Attribution
The September quarter was a rollercoaster for U.S. equities. Stocks rallied strongly to the mid-point of the quarter, then peaked, and then sold off sharply for the second half retesting the June lows. The first half rally was fueled by optimism that inflation was showing signs of easing, low valuations and better than expected earnings. The sharp retest was driven by inflation data easing more slowly than expected, the Fed’s continued hawkish policy and the market’s fear that the Fed will drive the economy into a hard landing or a pending crisis.
View All Commentary